首页|127例非小细胞肺癌免疫治疗不良反应分析

127例非小细胞肺癌免疫治疗不良反应分析

扫码查看
目的:分析127例非小细胞肺癌(non-small cell lung cancer,NSCLC)免疫治疗药物不良反应(adverse reaction,ADR)的发生特点及临床表现,为临床及时发现和控制用药安全风险提供依据.方法:提取医院2019年7月—2023年5月住院患者免疫治疗的127例NSCLC的ADR发生情况,并按照患者的性别和年龄、ADR累及的器官/系统及临床表现、引起ADR用药亚组等维度进行统计及复杂网络分析.结果:127例患者中,有114例患者发生ADR,其中男性患者91例,占比79.82%,60~74岁年龄组ADR患者最多,共50例(43.86%);ADR以消化系统、血液/淋巴系统的损害最为多见,恶心55例、呕吐53例、骨髓抑制48例.结论:60岁以上NSCLC患者在接受免疫治疗时发生ADR事件概率高,尤其是消化系统和血液/淋巴系统,由于血液/淋巴系统ADR对疾病疗效影响较大,临床应重点监测血液/淋巴系统ADR.
Analysis of adverse reactions in immunotherapy for 127 cases of non-small cell lung cancer
Objective:To analyze the occurrence characteristics and clinical manifestations of adverse reactions(ADR)of immunotherapy in 127 cases of non-small cell lung cancer(NSCLC),and to provide evidence for timely detection and control on the risks of drug safety.Methods:127 patients with NSCLC treated with immunotherapy from July 2019 to May 2023 were analyzed by gender and age,ADR-involved organs/systems and clinical manifestations,and ADR subgroups.Results:Among 127 patients,114 patients had ADR,of which 91 were male,accounting for 79.82%.ADR patients aged 60 to 74 years were the most common,accounting for 50 cases(43.86%).The most common ADR was digestive system and blood/lymphatic system damages,and nausea in 55 cases,vomiting in 53 cases,myelosuppression in 48 cases.Conclusion:There is a high probability of ADR events in NSCLC patients over 60 years old receiving immunotherapy,especially in the digestive system and the blood/lymphatic system.Since ADR of the blood/lymphatic system has a great impact on the therapeutic effect of the disease,the adverse reactions of the blood/lymphatic system should be monitored clinically.

non-small cell lung cancerprogrammed death-1programmed death-ligand 1adverse reactionsanalysis and evaluationcomplex networkdrug safety

李凤、梁燕、边原、方强、周进、周俊翔、王怡鑫

展开 >

电子科技大学附属肿瘤医院/四川省肿瘤医院,成都 610041

电子科技大学医学院,成都 611731

电子科技大学附属四川省人民医院药学部,成都 610072

非小细胞肺癌 程序性死亡受体1 程序性死亡配体1 不良反应 分析评价 复杂网络 用药安全

四川省科技厅应用基础研究项目

2021YJ0118

2024

中国新药杂志
中国医药科技出版社 中国医药集团总公司 中国药学会

中国新药杂志

CSTPCD北大核心
影响因子:1.039
ISSN:1003-3734
年,卷(期):2024.33(15)
  • 13